Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Eisai India and GlaxoSmithKline (GSK) have signed an agreement to co-promote Paritec (rabeprazole sodium) in India. Paritecis, developed by Eisai, is a proton pump inhibitor, approved for the treatment of acid-related disorders like peptic ulcer, reflux gastric disorders. Eisai is the first Japanese pharmaceutical major to enter India through a 100% subsidiary consequent to the enactment of Patent Act by the country.
Subscribe to our email newsletter
S. Kalyanasundaram, Managing Director, GlaxoSmithKline, India and Vice President of South Asia GSK International, said: “We are pleased to enter into this co-promotion agreement with Eisai to facilitate the launch of Paritec in the Indian pharmaceutical market.”
GSK promotes a range of ethical formulations and is focussed in therapeutic areas of respiratory, dermatology and vaccines, besides having a presence in the areas of gastroenterology, dietary supplements, gynecology, neurology, cardiovascular and intensive care.
Eisai is a Japan-based company engaged in the discovery, development and marketing of pharmaceutical products for global usage.